Here are the G-BA decisions from the G-BA meeting held on 4 July 2024 on the early benefit assessments of Agamree, Loargys, Elrexfio, Evkeeza, and Ondexxya.
A complete database of all previous G-BA resolutions is available upon request.
- Agamree (vamorolone); Duchenne muscular dystrophy, ≥ 4 years – Orphan drug, Hint of not-quantifiable additional benefit
- Loargys (pegzilarginase); hyperargininemia (ARG1-D), ≥ 2 years – Orphan drug, Hint of not-quantifiable additional benefit
- Elrexfio (elranatamab); multiple myeloma, at least 3 previous therapies – Additional benefit not proven in both subgroups
- Evkeeza (evinacumab)
- homozygous familial hypercholesterolemia, ≥ 12 years – Additional benefit not proven
- homozygous familial hypercholesterolemia, ≥ 5 to < 12 years – Additional benefit not proven
- Ondexxya (andexanet alfa); reversal of anticoagulation after treatment with apixaban or rivaroxaban due to life-threatening or uncontrollable bleeding) – Time restriction of previous decision extended to 1 July 2025
Follow me on Instagram to never miss the latest G-BA decisions: